OSL Stock Overview
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia.
OncoSil Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.036|
|52 Week High||AU$0.081|
|52 Week Low||AU$0.033|
|1 Month Change||-33.33%|
|3 Month Change||-7.69%|
|1 Year Change||-36.84%|
|3 Year Change||-34.54%|
|5 Year Change||-64.00%|
|Change since IPO||-82.00%|
Recent News & Updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|OSL||AU Life Sciences||AU Market|
Return vs Industry: OSL exceeded the Australian Life Sciences industry which returned -43.4% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned -11.3% over the past year.
|OSL Average Weekly Movement||24.3%|
|Life Sciences Industry Average Movement||15.5%|
|Market Average Movement||9.7%|
|10% most volatile stocks in AU Market||16.3%|
|10% least volatile stocks in AU Market||4.2%|
Stable Share Price: OSL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 24% a week.
Volatility Over Time: OSL's weekly volatility has increased from 14% to 24% over the past year.
About the Company
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013.
OncoSil Medical Fundamentals Summary
|OSL fundamental statistics|
Is OSL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OSL income statement (TTM)|
|Cost of Revenue||AU$1.27m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.011|
|Net Profit Margin||-884.84%|
How did OSL perform over the long term?See historical performance and comparison
Is OSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OSL?
Other financial metrics that can be useful for relative valuation.
|What is OSL's n/a Ratio?|
Price to Sales Ratio vs Peers
How does OSL's PS Ratio compare to its peers?
|OSL PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BPH BPH Energy
PIQ Proteomics International Laboratories
EZZ EZZ Life Science Holdings
OSL OncoSil Medical
Price-To-Sales vs Peers: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the peer average (22.9x).
Price to Earnings Ratio vs Industry
How does OSL's PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the Global Life Sciences industry average (5.3x)
Price to Sales Ratio vs Fair Ratio
What is OSL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||27.9x|
|Fair PS Ratio||3.5x|
Price-To-Sales vs Fair Ratio: OSL is expensive based on its Price-To-Sales Ratio (27.9x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Share Price vs Fair Value
What is the Fair Price of OSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OSL's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OSL's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is OncoSil Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OSL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OSL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OSL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OSL's revenue (6.9% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: OSL's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OSL is forecast to be unprofitable in 3 years.
Discover growth companies
How has OncoSil Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OSL is currently unprofitable.
Growing Profit Margin: OSL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.5%).
Return on Equity
High ROE: OSL has a negative Return on Equity (-180.83%), as it is currently unprofitable.
Discover strong past performing companies
How is OncoSil Medical's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OSL's short term assets (A$7.5M) exceed its short term liabilities (A$1.4M).
Long Term Liabilities: OSL's short term assets (A$7.5M) exceed its long term liabilities (A$234.2K).
Debt to Equity History and Analysis
Debt Level: OSL is debt free.
Reducing Debt: OSL had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OSL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OSL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.3% each year
Discover healthy companies
What is OncoSil Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OSL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nigel Lange serves as Chief Executive officer, Managing Director and Director of OncoSil Medical Limited since January 21, 2021. He served as President of EMEA at OncoSil Medical Limited since May 2020...
CEO Compensation Analysis
Compensation vs Market: Nigel's total compensation ($USD669.77K) is above average for companies of similar size in the Australian market ($USD288.24K).
Compensation vs Earnings: Insufficient data to compare Nigel's compensation with company performance.
Experienced Management: OSL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: OSL's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.
OncoSil Medical Limited's employee growth, exchange listings and data sources
- Name: OncoSil Medical Limited
- Ticker: OSL
- Exchange: ASX
- Founded: 2005
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$35.685m
- Shares outstanding: 991.24m
- Website: https://www.oncosil.com.au
- OncoSil Medical Limited
- 15 Blue Street
- Suite 503
- North Sydney
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.